ir.vikingtherapeutics.com
Viking Therapeutics – Investors – OverviewNovel therapeutics for metabolic and endocrine disorders.
http://ir.vikingtherapeutics.com/
Novel therapeutics for metabolic and endocrine disorders.
http://ir.vikingtherapeutics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
1.6 seconds
16x16
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
62
SITE IP
23.0.160.10
LOAD TIME
1.56 sec
SCORE
6.2
Viking Therapeutics – Investors – Overview | ir.vikingtherapeutics.com Reviews
https://ir.vikingtherapeutics.com
Novel therapeutics for metabolic and endocrine disorders.
Viking Therapeutics – VK5211 for Hip Fracture
http://www.vikingtherapeutics.com/pipeline/vk5211
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. VK5211 for Hip Fracture. In a pre-clinical model of osteoporosis, VK5211 demonstrated improvements in bone mineral density, bone mineral content, bone strength, and other measures. We believe VK5211’s potential stimulatory effect on lean body mass and bone mineral density could result in benefits to patients recovering from hip fracture surgery. Goals of SARM Therapy. In this clinical t...
Viking Therapeutics – VK0612 for Type 2 Diabetes
http://www.vikingtherapeutics.com/vk0612
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. VK0612 for Type 2 Diabetes. Phase 2a Proof-of-Concept Summary. Day 28 vs. Baseline ΔFPG (mg/dL). Statistically and clinically significant glucose lowering. Efficacy further improves with increasing disease severity, subjects with baseline FPG 180 mg/dL experienced -49.7 mg/dL improvement (p = 0.0099); compares favorably to current therapies. VK0612: 14-Day Phase 1b Efficacy Results.
Viking Therapeutics – Advisors
http://www.vikingtherapeutics.com/about/advisors
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. David Bullough, Ph.D. VP, Preclinical Development, RaNA. Former Executive Director, Metabolic Diseases, Pfizer. Former VP and Head of Pharmaceutical and Preclinical Development, Metabasis Therapeutics. Alan D. Cherrington, Ph.D. Professor of Molecular Physiology and Biophysics, Professor of Medicine, Turner Chair in Diabetes Research, Vanderbilt University Medical Center. We are focused...
Viking Therapeutics – EPOR Agonist Program
http://www.vikingtherapeutics.com/pipeline/epor
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. Erythropoietin (EPO) acts on its receptor to stimulate the differentiation of bone marrow hematopoietic cells to form red blood cells. Various recombinant human EPO derivatives are marketed as erythropoiesis-stimulating agents (ESAs) for the treatment of anemia due to renal failure or cancer chemotherapy (e.g., AranespTM, EpogenTM, EprexTM, and ProcritTM).
Viking Therapeutics – Thyroid Receptor beta Agonists for Lipid Disorders
http://www.vikingtherapeutics.com/pipeline/vk0214
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. Thyroid Receptor beta Agonists for Lipid Disorders. Predominantly in the liver and brain. Modulates cholesterol and triglyceride levels. Predominantly in cardiac tissue. Modulates heart rate, contraction. Therapeutic goal for lipid-targeting:. In animal models of hypercholesterolemia, or high levels of cholesterol in the blood, both VK2809. Effects of VK2809 on plasma cholesterol. We ar...
Viking Therapeutics – Focus
http://www.vikingtherapeutics.com/focus
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. Hip Fracture and Muscle Wasting. SARMs and Anabolic Metabolism. We believe VK5211’s selectivity, limited off-target effects and convenient oral route of administration may make it an attractive potential treatment option for patients recovering from non-elective hip fracture surgery. A Global Healthcare Issue. Worldwide prevalence estimated at 300M (IDF 2012). 19M new diagnoses annually.
Viking Therapeutics – DGAT-1 Inhibitor Program
http://www.vikingtherapeutics.com/pipeline/dgat-1
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. DGAT-1 Mediates Absorption of Fats from the GI Tract. Inhibition of DGAT-1 in the enterocyte reduces post-prandial fat deposition; increases nutrient sensing, satiety. Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. We are focused on specialty metabolic and endocrine indications.
Viking Therapeutics – Viking Therapeutics
http://www.vikingtherapeutics.com/about
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. Viking Therapeutics is focused on the development of novel therapeutics for patients suffering from metabolic and endocrine disorders. Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. We are focused on specialty metabolic and endocrine indications.
Viking Therapeutics – VK0612 for Type 2 Diabetes
http://www.vikingtherapeutics.com/pipeline/vk0612
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. VK0612 for Type 2 Diabetes. Phase 2a Proof-of-Concept Summary. Day 28 vs. Baseline ΔFPG (mg/dL). Statistically and clinically significant glucose lowering. Efficacy further improves with increasing disease severity, subjects with baseline FPG 180 mg/dL experienced -49.7 mg/dL improvement (p = 0.0099); compares favorably to current therapies. VK0612: 14-Day Phase 1b Efficacy Results.
Viking Therapeutics – Pipeline Overview
http://www.vikingtherapeutics.com/pipeline/overview
VK5211 for Hip Fracture. Thyroid Receptor beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. News & Events. We have a portfolio of five drug candidates in clinical trials or preclinical studies. Our lead clinical program, VK5211. Our second pipeline program is focused on the development of novel small molecule agonists of the thyroid beta (TRb) receptor, VK2809. We are also developing VK0612. We are also developing preclinical programs targeted at metabolic diseases and anemia.
TOTAL LINKS TO THIS WEBSITE
62
Investor Overview - Versartis
Annual Reports and Proxies. Versartis, Inc. is an endocrine-focused biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders. Versartis was founded in December 2008 and is headquartered in Menlo Park, California, USA. 4:00 PM ET on Aug 17, 2015. Delayed at least 20 minutes. Aug 11, 2015. Versartis to Host Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency. Aug 4, 2015. View all press releases ». Canaccord ...
Vestas Wind Systems A/S - Mobile Investor
5:04 PM ET - Aug 7, 2015. Jul 9, 2015. Information in the market regarding project in the USA. Jun 30, 2015. Vestas receives 108 MW order in the USA. Jun 30, 2015. Vestas receives 274 MW order in the USA. Jun 30, 2015. Vestas receives 155 MW order in the USA. Jun 29, 2015. Information in the market regarding MHI Offshore Wind and an offshore project in Denmark. Nov 7, 2014. Disclosure of Q3 2014. Aug 20, 2014. Disclosure of Q2 2014. May 9, 2014. Disclosure of Q1 2014. Mar 24, 2014. Feb 28, 2014.
Investor Relations Overview
105 Corporate Center Blvd. Outdoor and Action Sports. VF Licensed Sports Group. Outdoor and Action Sports. VF Corporation Resources & Media. News / Events / Presentations. News and Media Inquiries. Associate Ethics and Benefits. Slide" data-cycle-swipe="true" data-cycle-timeout=0 data-cycle-log=false data-cycle-pager=" .pager" data-cycle-prev=" .prev" data-cycle-next=" .next". Deliver consistent, long-term value to shareholders by creating sustainable, profitable growth for our brands. Dec 19, 2016.
Viacom Inc. - Investor Relations
VIAB (Class B Stock). Data as of 03/29/18 4:00 PM ET. Minimum 20 minute delay. Deutsche Bank 26th Annual Media, Telecom and Business Services Conference. 03/5/18 at 1:40 PM ET. 1st QUARTER 2018 EARNINGS MATERIALS. 1st Quarter '18 Earnings Trending Schedules. 1st Quarter '18 Earnings Presentation. 1st Quarter '18 Earnings Press Release. Mar 26, 2018. Viacom Announces Strategic Partnership with Trevor Noah's Day Zero Productions. Mar 24, 2018. VIACOM'S USE OF SOCIAL MEDIA. Frequently Asked Questions (FAQs).
VietstockIR- Bình chọn Top 5 DNNY có hoạt động IR tốt nhất năm 2016
Tổ chức tham gia. Bình chọn top 5 dnny. Có hoạt động ir tốt nhất 2016. KHẢO SÁT TOP 5 DNNY CÓ HOẠT ĐỘNG IR TỐT NHẤT 2016. Hạn cuối tham gia khảo sát 05/10/2016. Chương trình Bình chọn doanh nghiệp niêm yết có hoạt động IR tốt nhất. Là chương trình được xây dựng định kỳ hàng năm nhằm mục đích chọn ra những doanh nghiệp niêm yết có hoạt động quan hệ nhà đầu tư (IR - Investor Relations) xuất sắc nhất. Bình chọn đã diễn ra. LỄ TRAO GIẢI 2014. LỄ TRAO GIẢI 2014. LỄ TRAO GIẢI 2015. LỄ TRAO GIẢI 2014.
Viking Therapeutics – Investors – Overview
VK5211 for Hip Fracture. Thyroid beta Agonists for Lipid Disorders. VK0612 for Type 2 Diabetes. 160; 0.46. Data as of 08/17/15 3:59 pm ET. Minimum 20 minute delay. Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update. Viking Therapeutics to Conduct Phase 2 Trial of VK2809 in Patients With Cholesterolemia and Fatty Liver Disease. SAN DIEGO, CA - (Marketwired) - 07/14/15 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
Vipshop - Investor Relations - Home
The Brand Partner Advantage. Q2 2015 Vipshop Holdings Ltd Earnings Conference Call. 160;at 8:00 am ET. Q2 2015 Vipshop Holdings Ltd Earnings Conference Call. Tuesday, August 11, 2015 . 8:00 am ET . Click here for webcast. Click here to add this event to your calendar. 160; 0.44. Data as of 08/14/15 4:01 pm ET. Minimum 20 minute delay. Vipshop Reports Unaudited Second Quarter 2015 Financial Results. Vipshop to Announce Second Quarter 2015 Financial Results. Vipshop Responds to Additional Allegations.
Overview :: Viper Energy Partners LP (VNOM)
Navigate Viper Energy Partners LP. 1,329,696,240. Data Provided by Thomson Reuters. Minimum 20 minutes delayed. Go to Detailed Stock Info. There are currently no events scheduled. Viper Energy Partners LP, a Subsidiary of Diamondback Energy, Inc., Reports Second Quarter 2015 Cash Distributions and Financial and Operating Results and Provides Updated 2015 Guidance. Go to Press Releases. Visit our FAQs for common questions and answers. Viper Energy Partners LP. Midland, TX 79701. Sign up for Email Alerts.
Vipshop - Investor Relations - Home
The Brand Partner Advantage. Q2 2015 Vipshop Holdings Ltd Earnings Conference Call. 160;at 8:00 am ET. Q2 2015 Vipshop Holdings Ltd Earnings Conference Call. Tuesday, August 11, 2015 . 8:00 am ET . Click here for webcast. Click here to add this event to your calendar. 160; 0.93. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. Vipshop to Announce Second Quarter 2015 Financial Results. Vipshop Responds to Additional Allegations. Vipshop Responds to Recent Allegations. Q1 2015 Financial Results.
Virgin America - Investor Overview
Virgin America’s young and fuel efficient Airbus A320 aircraft. Virgin America Main Cabin Select. Virgin America First Class. Virgin America Main Cabin Select. Virgin America Main Cabin. Virgin America First Class. Virgin America’s sleek and sustainable home at San Francisco International Airport - Terminal 2. Virgin America is the only U.S. airline to offer WiFi and live television on every flight. Virgin America is the only domestic airline to offer on-demand drink and food ordering. Virgin America Liv...
Welcome » Investors » VirnetX
Seamless, Automatic, Internet Security. Seamless, Automatic, Internet Security. GABRIEL CONNECTION TECHNOLOGY WHITE PAPER. ROYALTY RATES AND GUIDELINES. VirnetX: Seamless, Automatic, Internet Security. Zephyr Cove, NV 89448. Phone: 775.548.1785. Fax: 775.580.7527. Zephyr Cove, NV 89448. 2014 VirnetX. Privacy policy.
